Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giada Bianchi

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
JACC. Cardiovascular Imaging|September 7, 2023
Cardiac Amyloid Quantification Using <sup>124</sup>I-Evuzamitide (<sup>124</sup>I-P5+14) Versus <sup>18</sup>F-Florbetapir: A Pilot PET/CT StudyOlivier F Clerc, Sarah A M Cuddy, Matthew Robertson, et al.
Blood|January 24, 2009
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Expert Review of Hematology|July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomideYuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
The EMBO Journal|February 25, 2006
Progressively impaired proteasomal capacity during terminal plasma cell differentiationSimone Cenci, Alexandre Mezghrani, Paolo Cascio, et al.
Leukemia|May 29, 2021
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myelomaSaad Z Usmani, Chatchada Karanes, William I Bensinger, et al.
JACC. Advances|May 15, 2025
Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert ConsensusNicole K Bart, Giada Bianchi, Sarah A M Cuddy, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
JACC. Cardiovascular Imaging|September 7, 2023
Cardiac Amyloid Quantification Using <sup>124</sup>I-Evuzamitide (<sup>124</sup>I-P5+14) Versus <sup>18</sup>F-Florbetapir: A Pilot PET/CT StudyOlivier F Clerc, Sarah A M Cuddy, Matthew Robertson, et al.
Blood|January 24, 2009
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Expert Review of Hematology|July 26, 2024
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomideYuxin Liu, Clifton C Mo, Monique A Hartley-Brown, et al.
Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
The EMBO Journal|February 25, 2006
Progressively impaired proteasomal capacity during terminal plasma cell differentiationSimone Cenci, Alexandre Mezghrani, Paolo Cascio, et al.
Leukemia|May 29, 2021
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myelomaSaad Z Usmani, Chatchada Karanes, William I Bensinger, et al.
JACC. Advances|May 15, 2025
Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert ConsensusNicole K Bart, Giada Bianchi, Sarah A M Cuddy, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient SurveyNadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Pageof 10